Suppr超能文献

癌症微环境中的趋化因子及其在癌症免疫治疗中的相关性。

Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

作者信息

Nagarsheth Nisha, Wicha Max S, Zou Weiping

机构信息

Department of Surgery, University of Michigan School of Medicine, 109 Zina Pitcher Place, Ann Arbor, Michigan 48109, USA.

Graduate Programs in Immunology and Tumour Biology, University of Michigan, Ann Arbor, Michigan 48109, USA.

出版信息

Nat Rev Immunol. 2017 Sep;17(9):559-572. doi: 10.1038/nri.2017.49. Epub 2017 May 30.

Abstract

The tumour microenvironment is the primary location in which tumour cells and the host immune system interact. Different immune cell subsets are recruited into the tumour microenvironment via interactions between chemokines and chemokine receptors, and these populations have distinct effects on tumour progression and therapeutic outcomes. In this Review, we focus on the main chemokines that are found in the human tumour microenvironment; we elaborate on their patterns of expression, their regulation and their roles in immune cell recruitment and in cancer and stromal cell biology, and we consider how they affect cancer immunity and tumorigenesis. We also discuss the potential of targeting chemokine networks, in combination with other immunotherapies, for the treatment of cancer.

摘要

肿瘤微环境是肿瘤细胞与宿主免疫系统相互作用的主要场所。不同的免疫细胞亚群通过趋化因子与趋化因子受体之间的相互作用被募集到肿瘤微环境中,这些细胞群体对肿瘤进展和治疗结果具有不同的影响。在本综述中,我们聚焦于人类肿瘤微环境中发现的主要趋化因子;详细阐述它们的表达模式、调控机制及其在免疫细胞募集以及癌症和基质细胞生物学中的作用,并探讨它们如何影响癌症免疫和肿瘤发生。我们还讨论了联合其他免疫疗法靶向趋化因子网络用于癌症治疗的潜力。

相似文献

1
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.
Nat Rev Immunol. 2017 Sep;17(9):559-572. doi: 10.1038/nri.2017.49. Epub 2017 May 30.
2
CCL7 Signaling in the Tumor Microenvironment.
Adv Exp Med Biol. 2020;1231:33-43. doi: 10.1007/978-3-030-36667-4_4.
3
The chemokine network: a target in cancer biology?
Adv Drug Deliv Rev. 2006 Oct 1;58(8):962-74. doi: 10.1016/j.addr.2006.03.012. Epub 2006 Aug 15.
4
Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy.
Int J Mol Sci. 2021 Sep 10;22(18):9804. doi: 10.3390/ijms22189804.
5
Chemokine systems in oncology: From microenvironment modulation to nanocarrier innovations.
Int J Biol Macromol. 2024 May;268(Pt 1):131679. doi: 10.1016/j.ijbiomac.2024.131679. Epub 2024 Apr 17.
6
Improving homing in T cell therapy.
Cytokine Growth Factor Rev. 2017 Aug;36:107-116. doi: 10.1016/j.cytogfr.2017.06.009. Epub 2017 Jun 23.
8
Role of chemokine receptors in thyroid cancer and immunotherapy.
Endocr Relat Cancer. 2019 Aug;26(8):R465-R478. doi: 10.1530/ERC-19-0163.
9
Chemokines in cancer.
Cancer Immunol Res. 2014 Dec;2(12):1125-31. doi: 10.1158/2326-6066.CIR-14-0160.
10
Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor.
Mol Immunol. 2020 Jan;117:201-215. doi: 10.1016/j.molimm.2019.11.014. Epub 2019 Dec 10.

引用本文的文献

2
SMC2 as a potential prognostic biomarker in lung adenocarcinoma and its correlation with immune microenvironment.
Mol Clin Oncol. 2025 Aug 12;23(4):93. doi: 10.3892/mco.2025.2888. eCollection 2025 Oct.
4
Chemokines: humble yet mighty players in the tumour microenvironment.
Front Immunol. 2025 Aug 7;16:1601756. doi: 10.3389/fimmu.2025.1601756. eCollection 2025.
5
Targeting STING to disrupt macrophage-mediated adhesion in encapsulating peritoneal sclerosis.
Commun Biol. 2025 Aug 23;8(1):1266. doi: 10.1038/s42003-025-08662-z.
6
Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.
J Immunother Cancer. 2025 Aug 11;13(8):e011881. doi: 10.1136/jitc-2025-011881.
7
Predicting head and neck cancer response to radiotherapy with a chemokine-based model.
Sci Rep. 2025 Aug 4;15(1):28450. doi: 10.1038/s41598-025-13346-z.
8
Biased antagonism of a series of bicyclic CXCR2 intracellular allosteric modulators.
Front Pharmacol. 2025 Jul 14;16:1631129. doi: 10.3389/fphar.2025.1631129. eCollection 2025.
9
Inhibition of FAK promotes pancreatic cancer immunotherapy by mediating CXCL10 secretion to enhance CD8 T cell infiltration.
Oncoimmunology. 2025 Dec;14(1):2539442. doi: 10.1080/2162402X.2025.2539442. Epub 2025 Jul 28.

本文引用的文献

1
Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.
Oncoimmunology. 2016 Aug 12;5(8):e1105430. doi: 10.1080/2162402X.2015.1105430. eCollection 2016 Aug.
2
Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.
Oncoimmunology. 2015 Sep 2;5(8):e1082704. doi: 10.1080/2162402X.2015.1082704. eCollection 2016 Aug.
3
Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling.
Cancer Res. 2016 Jun 1;76(11):3156-65. doi: 10.1158/0008-5472.CAN-15-2528. Epub 2016 Apr 6.
4
Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.
Cell. 2016 May 19;165(5):1092-1105. doi: 10.1016/j.cell.2016.04.009. Epub 2016 Apr 28.
5
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
6
Biological and pathological activities of interleukin-22.
J Mol Med (Berl). 2016 May;94(5):523-34. doi: 10.1007/s00109-016-1391-6. Epub 2016 Feb 29.
7
Ectopic expression of the chemokine CXCL17 in colon cancer cells.
Br J Cancer. 2016 Mar 15;114(6):697-703. doi: 10.1038/bjc.2016.4. Epub 2016 Feb 18.
8
CCR9 in cancer: oncogenic role and therapeutic targeting.
J Hematol Oncol. 2016 Feb 16;9:10. doi: 10.1186/s13045-016-0236-7.
9
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Cancer Res. 2016 Jan 15;76(2):275-82. doi: 10.1158/0008-5472.CAN-15-1938. Epub 2015 Nov 13.
10
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验